Cellectar Biosciences Inc. Common Stock (CLRB)

About CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

11

Website

www.cellectar.com/

Fundamentals

1-day range

$2.51$2.55

Market cap

$20.14M

P/E (trailing)

—

P/E (forward)

-1.32

EPS (trailing)

$-7.41

Dividend yield

—

Beta

0.55

Avg. volume

91.4K

Dividend pay date

July 17, 2018

Forecasts

4 analyst ratings

Cellectar Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• CLRB

  Cellectar Biosciences Inc. Common Stock

  $2.54

  ▲ 0.00%
  Market cap $20.14MP/E —
  $2.2$6.52
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.92MP/E —
  $0.72$3.78
• GRDX

  GridAI Technologies Corp. Common Stock

  $4.05

  ▲ 1.00%
  Market cap $19.91MP/E —
  $1.65$6.93
• RKTO

  Rocket One Inc. Common Stock

  $0.7021

  ▼ 2.76%
  Market cap $19.75MP/E —
  $0.691501$2.45
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.08MP/E —
  $3.19$21.4
• NRSN

  NeuroSense Therapeutics Ltd. Ordinary Shares

  $0.4301

  ▼ 2.03%
  Market cap $19.00MP/E —
  $0.25$1.98
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $18.67MP/E —
  $0.8099$2.46

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
  SeekingAlpha · 8/18/2026
• Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow
  SeekingAlpha · 8/18/2026
• Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
  Benzinga · 8/14/2026
• Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
  Benzinga · 8/14/2026
• Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Cellectar Biosciences Q2 2026 Earnings Call Transcript
  Benzinga · 8/13/2026
• Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
  Benzinga · 8/13/2026

• Loren Stefan · July 8, 2026 · Grant

  15.0K
• Chad J. Kolean · July 7, 2026 · Grant

  92.0K
• Chanan-Khan Asher · July 7, 2026 · Grant

  25.0K
• Gu Andrew · July 7, 2026 · Grant

  25.0K
• Jarrod Longcor · July 7, 2026 · Grant

  118.0K
• Douglas J. Swirsky · July 7, 2026 · Grant

  37.5K
• James Caruso V · July 7, 2026 · Grant

  250.0K
• John Neis · July 7, 2026 · Grant

  25.0K
• DRISCOLL FREDERICK W · July 7, 2026 · Grant

  25.0K
• Jarrod Longcor · May 7, 2026 · Buy

  26.0K @ $0.01
• Jarrod Longcor · May 7, 2026 · Buy

  8.7K @ $2.88
• James Caruso V · May 7, 2026 · Buy

  26.0K @ $0.01
• James Caruso V · May 7, 2026 · Buy

  8.7K @ $2.88

Institutional Ownership

March 31, 2026

Total shares held

293.6K

Total value held

$769.4K

Institutional holders

17